TRANSACTION GRANTED EARLY TERMINATION—Continued

| ET date | Trans No. | ET req status | Party name |
|---|---|---|---|
| | 19983359 | G | The Shaw Group Inc. |
| | | G | Mr. Roger Bagwell. |
| | | G | Bagwell Brothers, Inc. |
| | 19983392 | G | Apollo Investment Fund IV. |
| | | G | Larry Addington. |
| | | G | Coal Ventures, Inc. |

**FOR FURTHER INFORMATION CONTACT:** Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

**Donald S. Clark,**

*Secretary.*

[FR Doc. 98–23154 Filed 8–27–98; 8:45 am]

**BILLING CODE 6750–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services announces the following advisory committee meeting.

*Name:* National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Populations.

*Times and Dates:* 9:30 a.m.–3:00 p.m., September 17, 1998.

*Place:* Conference Room 505A, Hubert H. Humphrey Building, 200 Independence Avenue S.W. Washington, D.C. 20201.

*Status:* Open.

*Purpose:* The Subcommittee on Populations will hold a meeting on September 17. At the meeting the Subcommittee plans to discuss and finalize its work plan and revised charge, review and comment on its report on Medicaid managed care data issues, and continue its work on survey integration, including briefings on several survey issues.

*Contact Person for More Information:* Substantive program information as well as a roster of subcommittee members may be obtained from Carolyn Rimes, lead Subcommittee staff, Health Care Financing Administration, DHHS, 7500 Security Boulevard, C–3–21–06, Baltimore, Maryland 21244–1850, telephone (410) 786–6620, or Marjorie S. Greenberg, Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436–7050. Additional information about the full Committee is available on the NCVHS website, where the tentative agenda for the Subcommittee meeting will also be posted when available: http://aspe.os.dhhs.gov/ncvhs

Dated: August 24, 1998.

**James Scanlon,**

*Director, Division of Data Policy.*

[FR Doc. 98–23172 Filed 8–27–98; 8:45 am]

**BILLING CODE 4151–04–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Agency for Toxic Substances and Disease Registry

### Notice of Availability of Funds Program Announcement 99006 Public Health Conference Support Grant Program; Amendment

A notice announcing the availability of Fiscal Year 1998 funds for the Public Health Conference Support Grant Program was published in the **Federal Register** on June 9, 1998, (Vol. 63 FR No. 110). The notice is amended as follows:

On page 31499, second column, under ''B. Eligible Applicants'', the first paragraph should read:

Applications may be submitted to CDC by public and private non-profit organizations and by governments and their agencies; that is, universities, colleges, research institutions, hospitals, other public and private non-profit organizations, State and local governments or their bonafide agents, and federally-recognized Indian tribal governments, Indian tribes, or Indian tribal organizations.

Dated: August 24, 1998.

**John L. Williams,**

*Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 98–23132 Filed 8–27–98; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Clinical Laboratory Improvement Advisory Committee (CLIAC).

*Times and Dates:* 8:30 a.m.–5 p.m., September 16, 1998; 8:30 a.m.–5 p.m., September 17, 1998.

*Place:* CDC, Koger Center, Williams Building, Conference Rooms 1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341.

*Status:* Open to the public, limited only by the space available. The meeting rooms accommodate approximately 85 people.

*Purpose:* This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

*Matters To Be Discussed:* The agenda will include an update on CLIA implementation; a report from the Genetic Testing Workgroup and discussions of revisions to general or specific CLIA requirements that apply to pre-analytic, analytic, and post-analytic components of genetic testing; and the applicability of CLIA to laboratory testing performed for assisted reproductive technology (ART).

Agenda items are subject to change as priorities dictate.

**CONTACT PERSON FOR ADDITIONAL INFORMATION:** John C. Ridderhof, Dr.

P.H., Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop G–25, Atlanta, Georgia 30341–3724, telephone 770/488–8076, FAX 770/488–8282.

Dated: August 24, 1998.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 98–23131 Filed 8–27–98; 8:45 am]

BILLING CODE 4163–18–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 97F–0213]**

### Asahi Denka Kogyo K.K.; Filing of Food Additive Petition; Amendment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the filing notice for a food additive petition filed by Asahi Denka Kogyo K.K. to indicate that the petitioned additive, phosphorous acid, cyclic neopentanetetrayl bis(2,6-di-*tert*-butyl-4-methylphenyl)ester is for use as an antioxidant and/or stabilizer in polypropylene homopolymer and copolymers not to exceed 0.25 percent by weight of polypropylene homopolymer and copolymers in contact with food. The previous filing notice indicated that the proposed additive was for use in olefin copolymers and polypropylene in contact with certain food categories.

**DATES:** Written comments on the petitioner's environmental assessment by September 28, 1998.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane., rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–206), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3086.

**SUPPLEMENTARY INFORMATION:** In a notice published in the **Federal Register** of June 9, 1997 (62 FR 31433), FDA announced that a food additive petition (FAP 7B4542) had been filed by Asahi Denka Kogyo K.K., Shirahata 5-Chome, Urawa City, Saitama 366, Japan, proposing that § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) be amended to provide for the expanded safe use of phosphorous acid, cyclic neopentanetetrayl bis(2,6-di-*tert*-butyl-4-methylphenyl)ester for use: (1) At levels not to exceed 0.25 percent by weight of olefin copolymers complying with § 177.1520 (21 CFR 177.1520) in contact with foods of types I, II, III, IV–B, VI–B, and VIII, as described in Table 1, and under conditions of use B through H, described in Table 2 of § 176.170(c) (21 CFR 176.170(c)), of this chapter, and with food types IV–A, V, VI–A, VI–C, VII–A, and IX, under conditions of use C through G, as described in § 176.170(c), Tables 1 and 2, respectively; and (2) at levels not to exceed 0.10 percent by weight of either olefin copolymers or polypropylene complying with § 177.1520, which may be used only in contact with foods of types IV–A, V, VI–C, VII–A, and IX, under conditions of use H, as described in § 176.170(c) of this chapter, Tables 1 and 2, respectively.

Upon further review of the petition, the agency noted that the data presented in the petition address use of the subject additive only in polypropylene homopolymer and polypropylene copolymers. The agency also noted that the data in the petition in combination with the data for those applications of the additive currently listed in § 178.2010, apply to the use of the subject additive in polypropylene homopolymer and copolymers in contact with all food types under conditions of use B through H as described in Table 2 of § 176.170(c). Based on this information, the petitioner agreed to amend its request. Therefore, FDA is amending the filing notice of June 9, 1997, to state that the petitioner requests that the food additive regulations be amended to permit use of the subject additive in polypropylene homopolymer and copolymers for all food types under conditions of use B through H.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 28, 1998, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 6, 1998.

**Laura M. Tarantino,**

*Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 98–23103 Filed 8–27–98; 8:45 am]

BILLING CODE 4160–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 96F–0248]**

### Life Technologies, Inc.; Filing of Food Additive Petition; Amendment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the filing notice for a food additive petition filed by Life Technologies, Inc., to provide for a change in the extraction requirements for sulphopropyl cellulose ion-exchange resin for the recovery and purification of proteins for food use.

**FOR FURTHER INFORMATION CONTACT:** Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3071.

**SUPPLEMENTARY INFORMATION:** In a notice published in the **Federal Register** of July 22, 1996 (61 FR 37905), FDA announced that a food additive petition (FAP 6A4502) had been filed by Life Technologies, Inc., 8400 Helgerman Ct., Gaithersburg, MD 20874 (now, 9800 Medical Center Dr., Rockville, MD 20850). The petition proposed to amend the food additive regulations in § 173.25(b)(5) *Ion-exchange resins* (21 CFR 173.25(b)(5)) to provide for a